GeoVax Labs, Inc. — Q3 2017 Form 10-Q
Reporting period: Three and nine months ended September 30, 2017. GeoVax is a clinical-stage biotechnology company developing vaccines using its MVA-VLP platform. Programs include HIV, Zika, hemorrhagic fever viruses, malaria, hepatitis B, and cancer; preventive HIV is its only program identified as being in human clinical trials. Revenue is from grants and collaboration fees, not product sales.
Financial results and liquidity
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Grant and collaboration revenue | $247,994 | $440,106 | $895,866 | $653,986 |
| Research and development | $498,200 | $683,939 | $1,568,093 | $1,519,519 |
| General and administrative | $340,143 | $220,707 | $985,001 | $1,472,030 |
| Operating loss | $590,349 | $464,540 | $1,657,228 | $2,337,563 |
| Net loss | $588,757 | $464,200 | $1,653,979 | $2,336,314 |
| Loss per common share | $0.01 | $0.01 | $0.03 | $0.06 |
At September 30, cash and cash equivalents were $343,826, total assets $495,635, and current liabilities $731,542. Working capital was a deficit of $285,401, compared with positive working capital of $174,532 at December 31, 2016. Stockholders’ equity was a deficit of $235,907. The filing reports no long-term debt or committed credit line. Accrued expenses totaled $613,411, including $598,411 of accrued management salaries and directors’ fees whose payment was being deferred.
For the first nine months, operating cash use was $1,240,021, investing cash use was $4,350, and financing provided $1,134,167. Cash declined by $110,204 from year-end 2016. No gross margin is reported; the filing describes grant revenue as approximately matching related costs.
Changes and notable transactions
- Q3 revenue declined from 2016, while nine-month revenue increased, reflecting the timing and level of grant-supported spending and a $95,000 AGT collaboration fee recognized in 2017.
- Nine-month net loss improved from 2016. General and administrative expense fell year over year, primarily reflecting substantially lower stock-based compensation; research and development expense increased modestly.
- In May 2017, GeoVax raised $980,000 net through Series D convertible preferred stock. It also received $154,167 net from warrant exercises in the first nine months. Series C conversion terms were reduced from $0.05 to $0.015 per share in connection with the Series D issuance.
- During the first nine months, 178 Series C preferred shares converted into 11,862,000 common shares. After quarter-end, a further 120 Series C shares converted into 8,000,000 common shares, and warrant exercises generated $75,000 net proceeds for 5,000,000 shares.
- Common shares outstanding were 70,913,900 at September 30 and 83,913,900 as of November 9, 2017. The company increased authorized common shares from 300 million to 600 million in August.
Outlook, risks, and commitments
- Management said cash and existing government funding commitments were expected to support planned operations into the first quarter of 2018. The filing states there is substantial doubt about the company’s ability to continue as a going concern beyond that point; management was pursuing additional grants, contracts, equity sales, warrant exercises, or other funding, but success and terms were uncertain.
- As of September 30, $744,769 of approved grant and contract funds remained available for use through June 30, 2018. Separately, a NIAID contract awarded in 2016 provides for up to $7.8 million for production of a DNA vaccine component for intended advanced clinical trials.
- The company expects continued operating losses and does not expect product-sale revenue for at least several years. Vaccine development, clinical and regulatory approval, competition, and access to capital are major risks; programs could be delayed, scaled back, or discontinued if funding is insufficient.
- Lease payments and other firm purchase commitments totaled approximately $274,000; about $79,000 of purchase commitments were expected to be reimbursed under government grants. The office and laboratory lease runs through December 2018, with a renewal option.
- Potential dilution is significant: approximately 277.5 million common-share equivalents were excluded from diluted loss per share as anti-dilutive at September 30, 2017. Series C and D preferred stock and warrants include conversion or price-adjustment features.
- No legal proceedings or material changes to previously disclosed risk factors were reported. Management concluded disclosure controls were effective, with no material change in internal control over financial reporting during the quarter.
Investor verification points
- Confirm the timing, amount, and terms of new funding needed beyond the first quarter of 2018, and reassess the going-concern disclosure.
- Track cash use, deferred compensation balances, grant reimbursements, and the availability and timing of the $744,769 in approved grant funds.
- Review the conversion and price-adjustment terms of Series C and Series D preferred stock, outstanding warrants, and resulting fully diluted share count.
- Monitor NIAID-supported HIV vaccine studies and the AGT collaboration, including trial progress, funding responsibility, and any future licensing or commercial rights.